Lea las actualizaciones de noticias oficiales actuales de la OMS y los CDC, que se enumeran a continuación en la sección Noticias, que descienden de las más recientes en la parte superior. Vea los avisos de ambas organizaciones asignados globalmente a continuación.**
Brotes de enfermedades de la OMS
Dengue fever – Pakistan...
Tue, 19 Nov 2019Health authorities in Pakistan are responding to an ongoing outbreak of dengue fever. This outbreak was first reported on 8 July 2019 by the Khyber Teaching Hospital in Peshawar, Khyber Pakhtunkhwa (KP) province. Since then, three other provinces (Punjab, Balochistan, and Sindh), as well as Islamabad Capital Territory (ICT), and Azad Jammu and Kashmir (AJK; one of the two autonomous territories) have also reported cases of dengue fever.
From 8 July to 12 November 2019, a total of 47,120 confirmed cases of dengue fever, including 75 deaths, were reported from the four provinces (KP, Punjab, Balochistan, and Sindh), Islamabad, and AJK.
Rift Valley Fever – Republic of the Sudan...
Thu, 14 Nov 2019On 10 October 2019, the National IHR Focal Point for Sudan notified WHO of 47 suspected cases of Rift Valley Fever (RVF), including two deaths in Arb’aat Area, Towashan Village, in El Qaneb locality, Red Sea State. The suspected cases presented with high-grade fever, headaches, joint pain, vomiting. There were no hemorrhagic signs or symptoms observed. The first case presented to the health facility on 19 September 2019.
On 28 September 2019, a total of 14 samples were sent to the National Public Health Laboratory in Khartoum, and 5 tested positive for RVF by Immunoglobulin M (IgM) enzyme-linked immunosorbent assay (ELISA) and reverse-transcriptase polymerase chain reaction (RT-PCR). These samples were also tested for malaria and were found negative.
Ebola virus disease – Democratic Republic of the Congo ...
Thu, 14 Nov 2019Six new confirmed cases were reported in the past week (6 to 12 November) in the ongoing Ebola virus disease (EVD) outbreak in North Kivu and Ituri provinces.
Avisos de viaje de CDC:
Watch - Dengue in Asia and the Pacific Islands...
Wed, 30 Oct 2019Dengue is a risk in many parts of Asia and the Pacific Islands. Some countries are reporting increased numbers of cases of the disease. Travelers to Asia and the Pacific Islands can protect themselves by preventing mosquito bites.
Alert - Ebola in Democratic Republic of the Congo...
Tue, 29 Oct 2019There is an outbreak of Ebola in the North Kivu (Kivu Nord) and Ituri provinces in the Democratic Republic of the Congo (DRC).
Watch - Dengue in the Mediterranean Region...
Wed, 09 Oct 2019Locally acquired dengue virus infection has been reported in France and Spain. The risk of infection to travelers to the Mediterranean region is low.
Alert - Polio in the Philippines...
Tue, 08 Oct 2019There is a polio outbreak in the Philippines.
Watch - Chikungunya in Ethiopia...
Tue, 08 Oct 2019There is an outbreak of chikungunya in Ethiopia. You can protect yourself against chikungunya disease by preventing mosquito bites
Haga clic aquí para buscar enfermedades relacionadas con los viajes por país.
El Asistente Clínico de Viajes (TCA) es del Departamento de Salud de Georgia.
Informe semanal de morbosidad y mortalidad de CDC (MMWR):
EARLY RELEASE: Update: Interim Guidance for Health Care Providers...
Tue, 19 Nov 2019As rates of influenza increase, providers evaluating patients with respiratory illnesses should ask them about e-cigarette, or vaping, product use.
EARLY RELEASE: Characteristics of Hospitalized and Nonhospitalize...
Tue, 19 Nov 2019This report provides updated data on patient demographic characteristics and substances used in e-cigarette, or vaping, products among hospitalized and nonhospitalized patients.
Actualizaciones de revistas académicas actualesSkip Actualizaciones de revistas académicas actuales
Clinical Infectious Diseases Journal
This list includes items from the latest issue of the Clinical Infectious Diseases Journal.
In Vitro Activity of Cefiderocol Against a Broad Range of Clinica...
Wed, 13 Nov 2019AbstractCarbapenem-resistant gram-negative bacteria including Enterobacteriaceae as well as nonfermenters, such as Pseudomonas aeruginosa and Acinetobacter baumannii, have emerged as significant global clinical threats. Although new agents have recently been approved, none are active across the entire range of resistance mechanisms presented by carbapenem-resistant gram-negative bacteria. Cefiderocol, a novel siderophore cephalosporin, has been shown in large surveillance programs and independent in vitro studies to be highly active against all key gram-negative causative pathogens isolated from patients with hospital-acquired or ventilator-associated pneumonia, bloodstream infections, or complicated urinary tract infections. The improved structure, the novel mode of entry into bacteria, and its stability against carbapenemases enables cefiderocol to exhibit high potency against isolates that produce carbapenemases of all classes or are resistant due to porin channel mutations and/or efflux pump overexpression. Resistance to cefiderocol is uncommon and appears to be multifactorial.
Pathogen-focused Clinical Development to Address Unmet Medical Ne...
Wed, 13 Nov 2019AbstractHistorically, the regulatory requirements of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for developing new antibiotics have not addressed pathogen-focused indications for drug approval. The design of the necessary randomized controlled trials traditionally involves the enrollment of patients with site-specific infections caused by susceptible as well as resistant pathogens. Cefiderocol has undergone a streamlined clinical development program to address serious carbapenem-resistant infections. The regulatory approach, and the pivotal clinical trials, differed between the FDA and EMA. In the United States, the APEKS-cUTI (Acinetobacter, Pseudomonas, Escherichia coli, Klebsiella, Stenotrophomonas–complicated urinary tract infection) study was conducted to provide the basis for FDA approval of a site-specific cUTI indication. The EMA, however, preferred the CREDIBLE-CR (A MultiCenter, RandomizED, Open-label ClInical Study of S-649266 or Best AvailabLE Therapy for the Treatment of Severe Infections Caused by Carbapenem-Resistant Gram-negative Pathogens) study, in which patients with nosocomial pneumonia, bloodstream infections, or cUTIs were enrolled if they had a carbapenem-resistant pathogen. The resulting European label will be pathogen focused rather than infection site specific (ie, treatment of gram-negative infection in patients with limited treatment options). The implications and limitations of these different regulatory processes are discussed.
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Nove...
Wed, 13 Nov 2019AbstractThe emergence of antimicrobial resistance is a significant public health issue worldwide, particularly for healthcare-associated infections caused by carbapenem-resistant gram-negative pathogens. Cefiderocol is a novel siderophore cephalosporin targeting gram-negative bacteria, including strains with carbapenem resistance. The structural characteristics of cefiderocol show similarity to both ceftazidime and cefepime, which enable cefiderocol to withstand hydrolysis by β-lactamases. The unique chemical component is the addition of a catechol moiety on the C-3 side chain, which chelates iron and mimics naturally occurring siderophore molecules. Following the chelation of iron, cefiderocol is actively transported across the outer membrane of the bacterial cell to the periplasmic space via specialized iron transporter channels. Furthermore, cefiderocol has demonstrated structural stability against hydrolysis by both serine- and metallo-β-lactamases, including clinically relevant carbapenemases such as Klebsiella pneumoniae carbapenemase, oxacillin carbapenemase-48, and New Delhi metallo-β-lactamase. Cefiderocol has demonstrated promising in vitro antibacterial and bactericidal activity, which correlates with its in vivo efficacy in several animal models. This article reviews the discovery and chemistry of cefiderocol, as well as some of the key microbiological and in vivo findings on cefiderocol from recently conducted investigations.
Listen: New England Journal of Medicine
The New England Journal of Medicine is a weekly general medicine journal, and this audio news feed presents interviews with specialists.
NEJM Interview: Dr. Kevin De Cock on the research and public heal...
Wed, 13 Nov 2019Dr. Kevin De Cock is the Kenya country director of the Centers for Disease Control and Prevention. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. K.M. De Cock, E. Zielinski-Gutiérrez, and S.B. Lucas. Learning from the Dead. N Engl J Med 2019;381:1889-1891.
NEJM Interview: Dr. Michael Fralick on contributors — and propo...
Wed, 06 Nov 2019Dr. Michael Fralick is an assistant professor in the Department of Medicine at the University of Toronto and a general internist at Mount Sinai Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. M. Fralick and A.S. Kesselheim. The U.S. Insulin Crisis — Rationing a Lifesaving Medication Discovered in the 1920s. N Engl J Med 2019;381:1793-1795.
NEJM Interview: Dr. Caleb Gardner on the limitations of an increa...
Wed, 30 Oct 2019Dr. Caleb Gardner is a psychiatrist who recently completed his residency at Cambridge Health Alliance. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. C. Gardner and A. Kleinman. Medicine and the Mind — The Consequences of Psychiatry’s Identity Crisis. N Engl J Med 2019;381:1697-1699.
Emerging Infectious Diseases Journal:
This list contains articles published online ahead of print.
Center for Infectious Disease Research and Policy:
News from the University of Minnesota Center for Infectious Disease Research and Policy (CIDRAP).
Euro health workers spotty on antibiotic knowledge...
Mon, 18 Nov 2019
Stewardship / Resistance Scan for Nov 18, 2019...
Mon, 18 Nov 2019EU antibiotic resistance responseGuidance on drug-resistant TB
Skipping measles vaccine tied to triple risk of disease spread...
Mon, 18 Nov 2019
Johns Hopkins Medicine RSS Feed:
Johns Hopkins Medicine science and medical news.
Study Shows Increased Risk of Uterine Fibroids in African-America...
Thu, 28 Dec 2017
In a study of medical records gathered on hundreds of thousands of African-American women, Johns Hopkins researchers say they have evidence that women with a common form of hair loss have an increased chance of developing uterine leiomyomas, or fibroids.
More Tumor Mutations Equals Higher Success Rate With Cancer Immun...
Wed, 20 Dec 2017
The “mutational burden,” or the number of mutations present in a tumor’s DNA, is a good predictor of whether that cancer type will respond to a class of cancer immunotherapy drugs known as checkpoint inhibitors, a new study led by
Johns Hopkins Kimmel Cancer Centerresearchers shows. The finding, published in the Dec. 21 New England Journal of Medicine, could be used to guide future clinical trials for these drugs.
How Electroconvulsive Therapy Relieves Depression Per Animal Expe...
Mon, 18 Dec 2017
In a study using genetically engineered mice, Johns Hopkins researchers have uncovered some new molecular details that appear to explain how electroconvulsive therapy (ECT) rapidly relieves severe depression in mammals, presumably including people. The molecular changes allow more communication between neurons in a specific part of the brain also known to respond to antidepressant drugs.
American Journal of Infection Control:
RSS feed including 'the latest published articles, both published in an issue and published as Articles in Press.'
Compliance with immunization and a biological risk assessment of...
2019-11-18According to the Occupational Health and Safety Risks in the Healthcare Sector guideline, 10% of workers in the European Union are employed in the health care industry, mostly in hospitals. In the performance of their jobs, however, health care workers (HCWs) are exposed to several workplace hazards, especially biological risks,1 which include infectious diseases. Moreover, there is also a risk that HCWs will spread diseases to colleagues and patients. The active immunization of HCWs is a primary prevention measure able to control and reduce the transmission of vaccine-preventable diseases (VPDs), particularly to patients at high risk (eg, those with cancer or immune deficits).
Considering high-risk activities and the presence of infection p...
2019-11-16We read the article titled “Current practice of infection control in Dutch primary care: Results of an online survey”1 with great interest. This study illustrates the need for infection prevention specialists in the outpatient setting, particularly physician offices. Physician offices can have a deceptively benign appearance in terms of infection prevention; however, history demonstrates differently.2 With physician offices, there are high-risk activities to consider, including reprocessing, injections, infusions, and procedures.
Effect of ultraviolet-C light disinfection at terminal patient d...
2019-11-16We employed an interrupted time series analysis to assess the impact of ultraviolet-C light disinfection at terminal discharge in an oncology unit and a bone marrow transplant unit on the incidence of hospital-acquired infections. The deployment of ultraviolet-C light disinfection was associated with a significant decrease in the rate of Clostridioides difficile infections and a significant decrease in the rate of central line–associated blood stream infections in the bone marrow transplant unit.